PMV Pharmaceuticals Statistics
Total Valuation
PMVP has a market cap or net worth of $72.96 million. The enterprise value is -$111.71 million.
Important Dates
The next estimated earnings date is Friday, March 7, 2025, before market open.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PMVP has 51.75 million shares outstanding. The number of shares has increased by 10.47% in one year.
| Current Share Class | 51.75M |
| Shares Outstanding | 51.75M |
| Shares Change (YoY) | +10.47% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 2.36% |
| Owned by Institutions (%) | 49.40% |
| Float | 37.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.98, with a Debt / Equity ratio of 0.07.
| Current Ratio | 13.98 |
| Quick Ratio | 13.48 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -23.63% and return on invested capital (ROIC) is -21.29%.
| Return on Equity (ROE) | -23.63% |
| Return on Assets (ROA) | -20.27% |
| Return on Invested Capital (ROIC) | -21.29% |
| Return on Capital Employed (ROCE) | -37.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$816,905 |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -16.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.88% in the last 52 weeks. The beta is 1.45, so PMVP's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -11.88% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 1.60 |
| Relative Strength Index (RSI) | 47.85 |
| Average Volume (20 Days) | 108,727 |
Short Selling Information
The latest short interest is 859,149, so 1.66% of the outstanding shares have been sold short.
| Short Interest | 859,149 |
| Short Previous Month | 1.38M |
| Short % of Shares Out | 1.66% |
| Short % of Float | 2.31% |
| Short Ratio (days to cover) | 5.18 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -78.59M |
| Pretax Income | -65.05M |
| Net Income | -51.47M |
| EBITDA | -77.12M |
| EBIT | -78.59M |
| Earnings Per Share (EPS) | -$1.00 |
Full Income StatementBalance Sheet
The company has $182.84 million in cash and $13.27 million in debt, giving a net cash position of $184.67 million or $3.57 per share.
| Cash & Cash Equivalents | 182.84M |
| Total Debt | 13.27M |
| Net Cash | 184.67M |
| Net Cash Per Share | $3.57 |
| Equity (Book Value) | 197.91M |
| Book Value Per Share | 3.82 |
| Working Capital | 176.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$46.71 million and capital expenditures -$796,000, giving a free cash flow of -$47.50 million.
| Operating Cash Flow | -46.71M |
| Capital Expenditures | -796,000 |
| Free Cash Flow | -47.50M |
| FCF Per Share | -$0.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |